Ascletis gets China license for Presidio HCV candidate

Presidio Pharmaceuticals Inc. (San Francisco, Calif.) granted Ascletis Pharmaceuticals Co. Ltd. (Hangzhou, China) exclusive development and commercialization rights to HCV candidate PPI-668 in China, Taiwan, Hong Kong and Macau.

Presidio received an undisclosed upfront payment and is eligible for milestones and tiered royalties. It retains ex-greater China rights to PPI-668, a second-generation HCV NS5A protein inhibitor in Phase II testing in the U.S. ...